AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to discuss ALT cut off and utlizing FIB-4 in primary care.
AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to explore the document’s key features and provide a high-level introduction.
AASLD has published new practice guidance on the clinical assessment and management of NAFLD. Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Ken Cusi to explore its key features and implications which place emphasis on advances in noninvasive risk stratification and therapeutics.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Mazen Noureddin to reflect on opening a new research institute, increasing optimism around drug trials and the use of NITs, work in the novel mitochondrial uncoupling agent HU6, the NAIL-NIT consortium and more.
Madrigal announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This final conversation discusses what the announcement could mean for combination therapy and adjacent drug development stories. Each panelist provides closing thoughts to the session, offering diverse perspectives and an array of key takeaways.
This week, Madrigal announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This conversation dives into the basic science of this study and the impact it will have on future use of NITs.
A highly anticipated NASH-TAG 2023 takes place in Park City, Utah on January 5-7, 2023. In this episode, Stephen Harrison previews the conference agenda and shares his perspective on Madrigal’s announcement of positive topline results from the MAESTRO-NASH trial of resmetirom.
This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This conversation dives into the implications of the Madrigal program, offering compelling commentary from a group of eight panelists with varying perspectives and takeaways.
This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. To commemorate what is primed to be a major breakthrough for the field, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the emerging story. This conversation offers varying first impressions and perspectives from the group of eight.
This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. To commemorate what is primed to be a major breakthrough for the field, Surfing the NASH Tsunami hosts an exclusive conversation with Founder and CEO of the Global Liver Institute, Donna Cryer.
